A U.S. Patent for “Stable IGG4 Based Binding Agent Formulations” was awarded to Sanofi on January 7th, 2020. The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis. Learn More